Hematological Malignancies
Oxcia AB’s clinical research is centered on blood cancers, with attention to advanced and relapsed/refractory disease settings. The current trial landscape includes acute myeloid leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma, and high-risk myelodysplastic syndromes.
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Diffuse Large B-Cell Lymphoma
- Multiple Myeloma
- High-risk Myelodysplastic Syndromes
The sponsor’s funded research reflects a focus on oncology within hematologic cancer treatment, including use in combination with other anti-cancer agents for progressive disease.
